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Objectives The purpose of this study was to characterize patients with mitral regurgitation (MR) and atrial fibrillation (AF)
treated percutaneously using the MitraClip device (Abbott Vascular, Abbott Park, Illinois) and compare the re-
sults with surgery in this population.
Background The EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) randomized controlled trial compared a less in-
vasive catheter-based treatment for MR with surgery, providing an opportunity to assess the impact of AF on the
outcomes of both the MitraClip procedure and surgical repair.
Methods The study population included 264 patients with moderately severe or severe MR assessed by an indepen-
dent echocardiographic core laboratory. Comparison of safety and effectiveness study endpoints at 30 days
and 1 year were made using both intention-to-treat and per-protocol (cohort of patients with MR 2 at
discharge) analyses.
Results Pre-existing AF was present in 27% of patients. These patients were older, had more advanced disease, and
were more likely to have a functional etiology. Similar reduction of MR to 2 before discharge was achieved
in patients with AF (83%) and in patients without AF (75%, p  0.3). Freedom from death, mitral valve surgery
for valve dysfunction, and MR 2 was similar at 12 months for AF patients (64%) and for no-AF patients
(61%, p  0.3). At 12 months, MR reduction to 2 was greater with surgery than with MitraClip, but
there was no interaction between rhythm and MR reduction, and no difference in all-cause mortality be-
tween patients with and patients without AF.
Conclusions Atrial fibrillation is associated with more advanced valvular disease and noncardiac comorbidities. However,
acute procedural success, safety, and 1-year efficacy with MitraClip therapy is similar for patients with AF and
without AF. (J Am Coll Cardiol 2012;59:1312–9) © 2012 by the American College of Cardiology Foundation
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April 3, 2012:1312–9 Atrial Fibrillation and Mitral Regurgitation in the EVEREST TrialAtrial fibrillation (AF) develops commonly in patients with
mitral regurgitation (MR), with a reported rate as high as
5% per year (1). Patients with both AF and MR have
increased rates of cardiac events (1,2). For this reason, the
onset of AF is considered a class IIa indication for mitral
valve surgery in patients with severe MR (3).
Surgical series of mitral repair or replacement have demon-
strated that patients with AF are older, have more comorbidi-
ties, and have more advanced disease (4–6). In some studies,
the outcomes of surgery in patients with AF have been similar
to those in patients without AF (4,7), whereas others have
reported worse surgical outcomes (8,9). Persistent AF after
surgery is associated with reduced medium- and long-term
survival (4–6,8,10).
Recently, a less invasive catheter treatment for MR with
the MitraClip device was compared with surgery in the
EVEREST II (Endovascular Valve Edge-to-Edge Repair Study)
randomized controlled trial (11,12). In the present analysis
of the EVEREST II study, we sought to determine: 1) the
effects of both surgery and MitraClip device (Abbott Vas-
cular, Abbott Park, Illinois) therapy with core laboratory
assessment of MR in AF patients who are older than those
in most prior series; 2) whether a less invasive therapy than
surgery would have a better outcome for AF patients than
for those in previous surgical series; and 3) whether AF
makes it more difficult to grasp leaflets with the MitraClip
device.
Methods
Study population. The study included 279 patients at 37
study centers in the United States and Canada who
Figure 1 Flow Chart of Study Population
The number of patients available for analysis at each time point are shown for the
ses]). *At 12 months, ITT patients who did not receive treatment (MitraClip device
analysis. FIB  fibrillation.participated in the randomized
EVEREST II study (11). A de-
tailed description of the trial
methodology, inclusion and ex-
clusion criteria, and the results
have been previously described
(11,12). Briefly, all patients had
moderately severe or severe mi-
tral regurgitation (3 or 4)
with a left ventricular (LV) ejec-
tion fraction 25%. Patients
ere symptomatic, or if asymp-
omatic, had a LV end-systolic
iameter of 40 mm to 55 mm, new AF, or pulmonary
ypertension. Patients were randomly allocated 2:1 to Mitra-
lip repair or surgery and the primary composite endpoint for
ffectiveness was freedom from death, from surgery for mitral
alve dysfunction, and from grade 3 or 4MR at 12 months.
he primary safety endpoint was the rate of major adverse
vents at 30 days. All echocardiograms were assessed by an
ndependent core laboratory, and quantitative and qualitative
R grading was performed according to the American Society
f Echocardiography guidelines (11,12).
low chart of AF patients. For this post-hoc analysis of
he EVEREST II randomized study, patients were classi-
ed on the basis of their baseline rhythm at the time of
andomization. The rhythm data were missing in 15 pa-
ients, leaving a total of 264 subjects available for analysis. A
ow chart detailing the patients available at various time-
oints stratified by analysis group, rhythm, and treatment
eceived is shown in Figure 1.
Abbreviations
and Acronyms
AF  atrial fibrillation
ITT  intention to treat
LA  left atrial
LV  left ventricular
MR  mitral regurgitation
NYHA  New York Heart
Association
PP  per protocol
tion-to-treat (ITT) population and also for the per-protocol cohort (PP [in parenthe-
tral valve surgery) were assumed to have 3 or 4 MR and were included in theinten
or mi
A  Ne
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Atrial Fibrillation and Mitral Regurgitation in the EVEREST Trial April 3, 2012:1312–9Statistical analysis. We performed all analyses according
to the intention-to-treat (ITT) principle. Where more
appropriate to compare actual treatments received, a
per-protocol (PP) analysis comparing only patients who
had successful percutaneous or surgical therapy (grade
2 MR at the time of hospital discharge) was utilized
and specified in the text. The PP analysis included 206
patients with known rhythm. Binary variables were com-
pared with Fisher’s exact test, and continuous variables
were compared with Student’s t test. A modified ridit
analysis was used to compare clinical success rates (free-
dom from death, mitral valve surgery, and MR 2)
between device and control groups at 12 months (13).
Changes in MR grade and New York Heart Association
Baseline Echocardiographic Parameters, Intention-to-Treat CohortTable 2 Baseline Echocardiographic Parameters, Intention-to-T
Parameters
All Patients
With AF
(n  72)
No AF
(n  192)
MR etiology functional 40% (29/72) 19%* (36/192)
MR grade 3 74% (53/72) 68% (131/192)
MR grade 4 18% (13/72) 28% (54/192)
LV EDV, ml 150 43 (n 72) 160 40 (n 190) 1
LV ESV, ml 64 27 (n 72) 62 25 (n 190)
LV EF, % 58 10 (n 72) 62 9* (n 190)
LA volume, ml 94 34 (n 70) 81 26* (n 184)
Septolateral annulus EDD, cm 3.9 0.4 (n 69) 3.9 0.5 (n 190)
Septolateral annulus ESD, cm 3.4 0.4 (n 69) 3.4 0.5 (n 190)
Values are % (n/N) or mean  SD. *p  0.05 atrial fibrillation (AF) versus no AF.
Baseline Characteristics of the Study PopulatioTable 1 Baseline Characteristics of the Stu
Characteristics Pre-Existing
n 72 (27%)
Male, female 67%, 33%
Age, yrs 72 11
Age 75 yrs 44%
Congestive heart failure 93% (67/7
Coronary artery disease 59% (42/7
History/myocardial infarction 33% (24/7
Peripheral vascular disease 13% (9/72
Hypertension 82% (59/7
Diabetes mellitus 13% (9/72
Chronic kidney disease 6% (4/72
COPD 21% (15/7
History of CABG 22% (16/7
History of PCI 26% (19/7
History of PPM 13% (9/70
History of ICD 14% (10/7
NYHA III and IV 56 (40/7
LVEF, % 58 10 (n
Afterload-reducing drugs 93% (42/4
Values are n (%), %, mean  SD, or % (n/N).
AF  atrial fibrillation; CABG  coronary artery bypass graft sur
cardioverter-defibrillator; LVEF  left ventricular ejection fraction; NYH
PPM  prior pacemaker.EDD  end-diastolic dimension; EDV  end-diastolic volume; EF  ejection fraction; ESD  end-syst
regurgitation.(NYHA) functional class from baseline to 12 months are
compared using Bowker’s test (14). All statistical analyses
were performed with the use of SAS for Windows
software, version 9.1 or higher (SAS Institute, Cary,
North Carolina).
Results
Baseline characteristics. The study population included
72 (27%) patients with AF and 192 (73%) patients
without pre-existing AF. Comparison of these patients is
shown in Table 1. Patients with AF were significantly
older (72  11 years vs. 64  13 years, p  0.0001) with
a larger percentage 75 years of age (44% vs. 23%, p 
Cohort
Device Patients Control Patients
ith AF
 45)
No AF
(n  130)
With AF
(n  27)
No AF
(n  62)
(15/45) 21% (27/130) 52% (14/27) 15%* (9/62)
(35/45) 67% (87/130) 67% (18/27) 71% (44/62)
(8/45) 29% (38/130) 19% (5/27) 26% (16/62)
43 (n 45) 158 38 (n 128) 151 44 (n 27) 163 46 (n 62)
27 (n 45) 62 24 (n 128) 65 28 (n 27) 62 27 (n 62)
10 (n 45) 62 9* (n 128) 58 10 (n 27) 63 10* (n 62)
33 (n 44) 82 25* (n 123) 91 37 (n 26) 80 27* (n 61)
0.4 (n 43) 3.9 0.5 (n 128) 3.9 0.5 (n 69) 3.9 0.5 (n 190)
0.4 (n 43) 3.4 0.5 (n 128) 3.4 0.5 (n 69) 3.4 0.5 (n 190)
pulation
No AF p Value
192 (73%)
63%, 37% 0.67
65 13 0.0001
23% 0.0013
84% (162/192) 0.0690
40% (76/192) 0.0053
16% (30/191) 0.0032
7% (13/192) 0.14
71% (136/192) 0.0834
7% (14/192) 0.22
2% (3/192) 0.0906
12% (23/192) 0.0752
17% (33/192) 0.38
18% (35/191) 0.17
3% (5/192) 0.0027
3% (6/192) 0.0021
47% (90/192) 0.22
62 9 (n 130) 0.0010
80% (104/130) 0.0386
OPD  chronic obstructive pulmonary disease; ICD  implantable
w York Heart Association; PCI  percutaneous coronary intervention;reat
W
(n
33%
78%
18%
50
64
58
95
3.9
3.4ndy Po
AF
2)
1)
2)
)
2)
)
)
1)
2)
2)
)
0)
2)
72)
5)
gery; Colic dimension; ESV  end-systolic volume; LA  left atrial; LV  left ventricular; MR  mitral
traClip
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April 3, 2012:1312–9 Atrial Fibrillation and Mitral Regurgitation in the EVEREST Trial0.0013). In addition, AF patients had more comorbidi-
ties, including a history of congestive heart failure,
coronary artery disease, previous myocardial infarction,
chronic kidney disease, chronic obstructive lung disease,
prior pacemaker, and lower LV ejection fraction. More
patients with AF were in NYHA functional class III or
IV and had a greater need for afterload-reducing medi-
cations (Table 1).
Echocardiographic parameters at baseline as assessed
by the echocardiographic core laboratory are compared by
treatment and rhythm in Table 2. The etiology of MR
was more likely to be functional in AF patients (40%) as
compared with patients without AF (19%), although the
majority of patients in all groups had degenerative valve
disease. The volume of the left atrium (LA) was larger in
AF patients (94  34 ml vs. 81  26 ml, p  0.05). The
grade of MR and LV volumes were similar in patients
with and patients without AF, and there were no differences
between the device group and control group (Table 2).
Acute procedural results. In MitraClip patients, acute
procedural success rates, procedural time, device time,
Safety to 30 Days, Intention-to-Treat PopulationTable 4 Safety to 30 Days, Intention-to-Trea
Device
Patients
With AF
(n  45)
Death 2.2% (1/45)
Myocardial infarction 0% (0/45)
Reoperation for failed MV surgery 0% (0/45)
Nonelective CV surgery for AE 6.7% (3/45)
Renal failure 2.2% (1/45)
Stroke 2.2% (1/45)
Deep wound infection 0% (0/45)
Septicemia 0% (0/45)
Ventilation 48 h 0% (0/45)
GI complication requiring surgery 2.2% (1/45)
Transfusion 2 units of blood 18% (8/45)
Total number patients with MAE* 22% (10/45)
Values are % (n/N). *Total number of patients with major adverse e
Procedural Results, Treatment Received, Per-Protocol CohortTable 3 Procedural Results, Treatment Received, Per-Protocol
Device Patients
With AF
(n  35)
Post-procedure ICU/CCU time, h 34 21 (n 35)
Post-procedure hospital stay, days 2.4 1.5 (n 35) 1
Discharged home 97% (34/35)
MitraClip procedure time,* min 177 78 (n 34) 1
MitraClip device time,† min 130 61 (n 33) 1
1 MitraClip implanted 54% (19/35)
2 MitraClips implanted 46% (16/35)
Values are mean  SD or % (n/N). *MitraClip procedure time is measured from the time the tran
time is measured from the time the SGC is placed in the intra-atrial septum until the time the Mi
CCU  cardiac care unit; ICU  intensive care unit; NA  not applicable.patients may experience 1 MAE.
AE adverse event; AF  atrial fibrillation; CV  cardiovascular; GI  gasand number of clips implanted were similar in patients
with AF and patients without AF (Table 3). Procedural
reduction of MR to 2 occurred at similar rates in
MitraClip patients with AF (83%, 35 of 42) compared
with MitraClip patients without AF (75%, 96 of 128;
p  0.30). When comparing all patients with AF or
without AF, patients with AF required longer post-
procedure stays both in the intensive care unit/cardiac
care unit and in the hospital (Table 3). The difference was
more marked in the control (surgical) patients. The
presence of AF added 0.8 days to the length of stay for
MitraClip patients, and 3.0 days for surgical patients.
Only 67% of surgical patients with AF could be dis-
charged to home as compared with 90% in the other
groups.
Permanent or persistent AF developed more often after
surgery (31%) than after MitraClip repair (16%). Among
patients undergoing surgery, a maze procedure was per-
formed in 11% of patients (37% of those with pre-operative
AF). An LA appendage ligation procedure was done in 22%
pulation
nts
vent
Control Patients
Patients With Event
No AF
(n  130)
With AF
(n  27)
No AF
(n  62)
8% (1/130) 3.7% (1/27) 1.6% (1/62)
0% (0/130) 0% (0/27) 0% (0/62)
0% (0/130) 3.7% (1/27) 0% (0/62)
8% (1/130) 7.4% (2/27) 3.2% (2/62)
0% (0/130) 0% (0/27) 0% (0/62)
8% (1/130) 3.7% (1/27) 1.6% (1/62)
0% (0/130) 0% (0/27) 0% (0/62)
0% (0/130) 0% (0/27) 0% (0/62)
0% (0/130) 14.8% (4/27) 0% (0/62)
8% (1/130) 0% (0/27) 0% (0/62)
2% (15/130) 63% (17/27) 37% (23/62)
2% (16/130) 67% (18/27) 40% (25/62)
AE) may not equal sum of patients in each row because individual
rt
Control Patients
o AF
 96)
With AF
(n  24)
No AF
(n  51)
7‡ (n 94) 150 116 (n 22) 55 48‡ (n 50)
.0‡ (n 96) 9.6 5.3 (n 24) 6.6 3.0‡ ((n 51)
(94/96) 58% (14/24) 77% (39/51)
2 (n 95) NA NA
9 (n 93) NA NA
(59/96) NA NA
(37/96) NA NA
procedure starts until the time the steerable guide catheter (SGC) is removed. †MitraClip device
Delivery System is retracted into the SGC. ‡p  0.05 atrial fibrillation (AF) versus no AF.t Po
Patie
With E
0.
0.
0.
0.
1
1
vents (MCoho
N
(n
24 1
.6 1
98%
83 7
41 6
62%
39%
sseptaltrointestinal; MV  mitral valve.
ther ab
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Atrial Fibrillation and Mitral Regurgitation in the EVEREST Trial April 3, 2012:1312–9of control (surgery) patients, half of whom had pre-
operative AF.
Device attachment to a single leaflet occurred more
often in patients with AF (13%) compared with patients
not having AF (3%, p  0.0194). Other protocol-defined
major adverse events to 30 days in device patients and
control patients stratified by rhythm are shown in Table 4.
The need for blood transfusion was higher for surgical
patients and trended higher for AF patients. There was 1
death and 1 stroke in each of the 4 study groups (device
and surgery with or without AF). The stroke in the device
patient with AF occurred after randomization but 1
month before MitraClip treatment. In the device patient
without AF, a stroke occurred after mitral valve surgery
after MitraClip treatment and resulted in death. The 2
strokes in the control (surgery) patients occurred imme-
diately post-operatively, and 1 resulted in death. There
Efficacy at 12 Months, Intention-to-Treat PopulaTable 5 Efficacy at 12 Months, Intention-to
All Patie
(n
Change baseline to 12 months
LV EDV, ml 21 2
LV ESV, ml 0.3 1
LA volume, ml 8 2
NYHA functional class I/II at 12 months 89%
MR grade (2) at 12 months 96%
SF-36 QOL change at 12 months
Mental component summary 6.6 1
Physical component summary 3.2 1
Values are mean  SD or % (n/N).
QOL  quality of life; SF-36  Short Form 36-Item Questionnaire; o
Figure 2 MR Grade at Baseline and at 12 Months
The change in mitral regurgitation (MR) grade (0 to 4) by rhythm (with or no atria
in the per-protocol cohort. Comparisons are between matched pairs of patients wiwere no other differences in major adverse events between
patients with AF or without AF.
Efficacy. The effects of therapy at baseline and 12 months
are shown for AF versus no AF in the entire (ITT)
population in Table 5, and stratified by treatment received
(PP population) in Figures 2, 3, and 4. Overall clinical
success in the ITT population, defined as freedom from
death, mitral valve surgery for valve dysfunction, and MR
2, was similar for AF patients (64%, 43 of 67) and
no-AF patients (61%, 114 of 188; p 0.33). The percent of
patients on afterload-reducing medication at 12 months was
lower in the no-AF group (65%) compared with the AF
group (72%), although the difference was not statistically
significant (p  0.31). A reduction in LV and LA volumes
was observed in both AF and no-AF patients, but was
significantly greater in patients without AF. A reduction in
MR grade (to 2) occurred more often in AF patients
t Population
th AF All Patients With No AF
(n  157)
p
Value
50) 34 33 (n 147) 0.0032
 50) 7.8 16.8 (n 147) 0.0023
43) 16 27 (n 130) 0.08
3) 97% (148/152) 0.020
2) 85% (130/153) 0.046
 45) 4.8 10.0 (n 137) 0.30
 45) 5.3 9.8 (n 136) 0.20
breviations as in Tables 1 and 2.
ation) is shown at baseline and at 12 months
entages in each labeled grade.tion-Trea
nts Wi
 57)
6 (n
3.3 (n
2 (n
(47/5
(50/5
0.8 (n
0.1 (nl fibrill
th perc
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April 3, 2012:1312–9 Atrial Fibrillation and Mitral Regurgitation in the EVEREST Trial(97%) as compared with no-AF patients (85%), with similar
improvement in NYHA class and Short Form-36 Health
Survey quality of life score (Table 5, Figs. 2 and 3).
The effects of therapy received (PP population) on MR
reduction is shown in Figure 2. Consistent with the
overall study, MR reduction was greater with surgery as
compared with MitraClip. However, there was no sig-
Figure 3 Freedom From All-Cause Mortality
Kaplan-Meier (KM) curves are shown for freedom from all-cause mortality dur-
ing 1 year for patients with pre-existing atrial fibrillation (Afib) (blue lines) or no
pre-existing atrial fibrillation (red lines). Groups shown are (A) all patients
(intention-to-treat [ITT] cohort); (B) patients receiving the MitraClip device (ITT
cohort); and (C) patients receiving the MitraClip device (per-protocol [PP]
cohort.nificant interaction between rhythm and MR reductionto 2 at 12 months for the entire study population,
device, or control groups (p  0.99). The freedom from
all-cause mortality at 1 year did not differ between AF
and no-AF patients (Fig. 3A), nor for MitraClip patients
examined both by ITT (Fig. 3B) or by therapy received
(Fig. 3C). Similarly, the freedom from mitral valve surgery
did not differ by rhythm in the same 3 analyses (Fig. 4).
Figure 4 Freedom From Mitral Valve Surgery
Kaplan-Meier (KM) curves are shown for freedom from mitral valve surgery dur-
ing 1 year for patients with pre-existing atrial fibrillation (Afib) (blue lines) or no
pre-existing atrial fibrillation (red lines). Groups shown are (A) all patients
(intention-to-treat [ITT] cohort); (B) patients receiving the MitraClip device (ITT
cohort); and (C) patients receiving the MitraClip device (per-protocol [PP]
cohort.
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Atrial fibrillation is common in patients with mitral
regurgitation referred for therapy, occurring at baseline in
27% of the EVEREST II study population. Similar to
prior surgical series, patients with MR and AF are older
and have more advanced valvular disease and noncardiac
comorbidities. Our patients with moderately severe or
severe MR as assessed by echocardiographic analysis in a
core laboratory were older than in most prior surgical
series. In addition, the patients with AF were on average
7 years older than patients without AF, had more
comorbidities, and required more medications. Although
the grade of MR and left ventricular dimensions were
similar between patients with AF and without AF, those
with AF had larger left atria and were more likely to have
a functional etiology of MR.
Despite the greater severity of MR and other illnesses in
patients with MR and AF, it appeared that the acute
procedural success of MitraClip therapy was similar for
patients with AF and without AF. Unlike some prior
surgical studies (8,9), surgery was not associated with
worse early outcome for AF patients in this study.
However, hospital length of stay was prolonged in AF
patients more after surgery (3 days) than after MitraClip
repair (0.8 days). This difference may be due, in part, to
other baseline differences between patients with AF and
without AF.
One might surmise that it would be more difficult to
grasp the mitral leaflets in patients with an irregularly
irregular rhythm; however, the MitraClip procedure and
device time were similar in patients with AF and without
AF. Device attachment to a single leaflet occurred in 10
patients, and significantly more frequently in AF patients
(13% vs. 3%). That may reflect greater difficulty in
assessing leaflet insertion echocardiographically during
AF and suggests the need for an even more careful
assessment of leaflet insertion in AF patients before clip
release. It is tempting to speculate as to whether conver-
sion to sinus rhythm before the procedure would reduce
this risk.
There was little difference in effectiveness as assessed by
the primary study endpoint (freedom from death, mitral
valve surgery for valve dysfunction, or MR 2) or by MR
reduction between AF patients and no-AF patients. In fact,
a reduction of MR to grade 2 occurred more often in
patients with AF (96%) than in patients without AF (85%)
(Table 5). At 1-year follow-up, there was no effect of
rhythm on all-cause mortality or the need for mitral valve
surgery.
The reduction in LA and LV volumes post-repair was
smaller in the patients with AF (Table 5). This finding
may reflect the larger initial chamber volumes in these
patients, as well as the potential for less LA and LV
remodeling or more persistent annular dilation after MR
repair in AF patients. It also raises the potential need foradditional rhythm strategies (pulmonary vein isolation
and/or surgical maze procedure) as an adjunctive thera-
peutic strategy.
Study limitations. This study is limited by its observa-
tional design and by the small number of patients with
AF. This analysis was not pre-specified, and the data
collected on rhythm at various time points are limited.
We cannot, therefore, differentiate between paroxysmal
and persistent or permanent AF, nor do we have data on
the duration of AF before enrollment. Finally, we do not
have data on the conversion rates to sinus rhythm during
follow-up.
Conclusions
Patients with MR and AF are sicker than patients who do
not have AF, but can undergo MitraClip repair with
overall procedural success, safety, and short-term efficacy
similar to that for patients without AF. The development
of AF is an indication for repair of MR. If a patient is
suitable for MitraClip repair, this therapy should be
considered independent of the presenting rhythm.
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